NCCN categories of preference will provide guidance on which recommendations within the NCCN Guidelines are optimal, while providing a range of recommendations to accommodate a variety of clinical circumstances.
September is Gynecologic Cancer Awareness Month. Many gynecologic cancers can be cured, but a delay in diagnosis can make cure more difficult. Experts at Rutgers Cancer Institute of New Jersey encourage women to "know their bodies."
Roswell Park Cancer has joined the Oncology Research Information Exchange Network, a unique research partnership among North America’s top cancer centers. Members of ORIEN contribute to a shared databank and collaborate on clinical research in order to develop new and better treatment options for cancer patients.
Women who receive a breast cancer diagnosis while they are still young enough to bear children can take time to freeze their eggs and embryos without fear of delaying their cancer treatment, according to research by UC San Francisco scientists who have helped develop a faster fertility preservation technique that can achieve in two weeks what used to take a month or longer.
Women who receive a breast cancer diagnosis while they are still young enough to bear children can take time to freeze their eggs and embryos without fear of delaying their cancer treatment, according to research by UC San Francisco scientists who have helped develop a faster fertility preservation technique that can achieve in two weeks what used to take a month or longer.
The University of California’s five academic cancer centers, home to some of the world’s leading scientists and physicians, have formed a consortium to better address California’s most pressing cancer-related problems and opportunities, UC President Janet Napolitano and Dr. John Stobo, executive vice president of UC Health, announced today.
The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited today announced a multi-year collaboration focused on accelerating the development of novel therapies for acute myeloid leukemia (AML).
A multigene panel test could be a useful diagnostic tool to help clinicians identify patients with a hereditary kidney cancer syndrome, according to the results of a study published in Cancer.
Not all kidney cancers are killers, and many small tumors can be left alone or watched over time because there is a low risk they will become dangerous, according to Dr. Brian Shuch at the Yale School of Medicine.
Ramucirumab plus docetaxel improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, according to late-breaking results from the phase III RANGE trial presented today at the ESMO 2017 Congress in Madrid (1) to be published in The Lancet (2).
William Atkinson is the 2017 recipient of the Julie and Ben Rogers Award for Excellence in Administration at The University of Texas MD Anderson Cancer Center. The annual award recognizes employees who consistently demonstrate excellence in their work and dedication to MD Anderson’s mission to end cancer. The award’s focus rotates annually among the areas of patient care, research, education, prevention and administration.
A new study from Roswell Park Cancer Institute reports that women with breast cancer who took multivitamin supplements were less likely to develop chemotherapy-induced neuropathy.
New research led by a team from Roswell Park Cancer Institute and published in the journal Nature Methods reports the development of the first tool for detecting changes in GTP levels in living cells.
Through dedicated teamwork, strategic planning and the support of its internal and external communities, The University of Texas MD Anderson Cancer Center has returned to full operations and continues to provide excellent care for thousands of cancer patients.
Researchers at UC Davis and other institutions have shown that mothers who take recommended amounts of folic acid around conception might reduce their children’s pesticide-related autism risk.
The UC Davis MND Institute has been awarded a 5-year, $12 million Autism Centers of Excellence (ACE) grant, one of five in the nation, to create a “Center for the Development of Phenotype-based Treatments of Autism Spectrum Disorder.”
Providing access to NCCN Templates® through MEDITECH’s Web EHR offers practitioners up-to-date, evidence-based cancer treatment protocols at the point of care to assist in shared decision-making.
There are approximately 57,000 newly diagnosed thyroid cancers annually. Do you know the signs and symptoms? A Rutgers Cancer Institute of New Jersey expert shares more.
An NCCN ORP-funded study, examining effectiveness of bavituximab combination in patients with newly diagnosed glioblastomas, enrolled its first patient at Dana-Farber Cancer Institute in Boston, Massachusetts.
TAMPA, Fla. – Cervical cancer is the second most common cause of cancer-related death worldwide, with almost 300,000 deaths occurring each year. More than 80 percent of these deaths occur in developing nations. The advent of human papillomavirus (HPV) vaccines has significantly reduced the number of those who develop and die from cervical cancer.
University of Colorado Cancer Center study shows that monitoring levels of blood tumor markers may predict when a lung cancer patient is progressing on targeted treatments.
Understanding a cancer’s genetics is key to selecting targeted therapies that are likely to be of the most benefit to a patient. The Ontario Institute for Cancer Research (OICR) today announced a new study, called Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (OCTANE). OCTANE will use next-generation genome sequencing technology to bring a unified molecular profiling approach to five Ontario cancer centres.
Braden’s Hope announced it will be awarding $3 million to advance childhood cancer research at The University of Kansas Cancer Center and Children’s Mercy. Braden’s Hope is a Kansas City-based charity that raises awareness and funds for precision-based research to cure childhood cancers.
A clinical trial testing the immunotherapy drug pembrolizumab shows the drug to be well tolerated among patients who have carcinoid or pancreatic neuroendocrine tumors. That’s according to investigators at Rutgers Cancer Institute of New Jersey and others. The work is being presented at the European Society for Medical Oncology 2017 Congress next week in Madrid.
Expanding its surgical and research focus on cancers of the abdominal area and rare conditions including endocrine and mesothelioma malignancies, Rutgers Cancer Institute of New Jersey has named H. Richard Alexander, MD, FACS, as its new chief surgical officer. He will be part of the Institute’s Gastrointestinal Oncology Program when he arrives this fall.
The National Cancer Institute (NCI) has named Peter M. Glazer, M.D., Ph.D., as a recipient of its Outstanding Investigator Award (OIA).
In new research published in the journal Cancer Research, a team from Roswell Park has shown that "beta blocker" drugs appear to be an effective means of reducing beta-2 receptor signaling and, in the process, may improve the efficacy of checkpoint inhibitor immunotherapy
A University of Colorado Cancer Center case study published today in the journal JCO Precision Oncology tests for alterations in many genes simultaneously, matching stage IV lung cancer patient with life-saving drug
A new biomedical tool using nanoparticles that deliver transient gene changes to targeted cells could make therapies for a variety of diseases — including cancer, diabetes and HIV — faster and cheaper to develop, and more customizable.
According to a recent study led by The University of Kansas Cancer Center researchers, a high proportion of smokers enrolled in bedside tobacco cessation programs who said they had quit were misreporting their smoking status.
In two papers published in the Journal of the National Cancer Institute researchers from UC Davis, UCLA and other institutions have found that peripheral neuropathy, which causes pain, numbness, and tingling in hands and/or feet, can bother early-stage breast cancer patients years after completing chemotherapy. In addition, a systematic literature review found only a handful of studies that tracked long-term peripheral neuropathy, leaving little data for patients and clinicians to make informed decisions.
Jennifer Tsui, PhD, a researcher at Rutgers Cancer Institute of New Jersey, has been awarded a $729,000 Mentored Research Scholar Grant in Applied and Clinical Research (MRSG-17-099-01-CPHSPS) from the American Cancer Society to further explore health care delivery and care transitions for underserved cancer patients.
The August tip sheet from Fred Hutch includes stories on breast cancer, skin cells as a cancer repair mechanism, an HIV prevention study, air pollution risk and more -- Here are quick summaries for journalists that offer sources and story ideas from Fred Hutch.
University of Colorado Cancer Center paper describes how immune response designed to scramble HPV DNA can scramble human DNA as well, sometimes in ways that cause cancer.
Rutgers Cancer Institute of New Jersey and the National Cancer Institute’s Center for Cancer Research are collaborating on work examining DNA repair in cancer thanks to $4 million in support including $2 million from the Robert Wood Johnson Foundation.
Cowboys for Cancer Research will hold its 35th annual dinner, dance and silent auction fundraising event to raise money and awareness for cancer research at The University of New Mexico Comprehensive Cancer Center and at New Mexico State University.
The immunotherapy drug pembrolizumab has demonstrated a favorable safety profile and “promising durable clinical activity” in pretreated patients who exhibit high levels of the PD-L1 protein in advanced stages of small cell lung cancer. That is according to data from a phase 1b clinical trial conducted by Rutgers Cancer Institute of New Jersey investigators and colleagues at centers around the world.
• Study explains why CDK4/6 inhibitors can shrink tumor in some advanced breast cancers • CDK4/6 inhibitors trigger the immune system to attack tumor cells • CDK4/6 inhibitors can also enhance anti-cancer effect of immunotherapy agents
Up to $14.8 million over five years, contingent on available funds, was announced today by The National Institutes of Health (NIH) Common Fund’s Gabriella Miller Kids First Pediatric Research Program (Kids First). Researchers in Canada and the United States are using these funds to join together and build a centralized, cloud-based database and discovery portal of genetic and clinical data called the Kids First Data Resource Center (DRC).
The University of New Mexico Comprehensive Cancer Center began helping New Mexicans with blood disorders a little more than one year ago. It is the state’s only bone marrow transplant program. The program offers treatment choices for people with lymphoma and myeloma and will expand to help people with other blood disorders.
It seems like such a simple question: Do patients whose tumors shrink more in response to targeted treatment go on to have better outcomes than patients whose tumors shrink less? But the implications of a recent study demonstrating this relationship are anything but simple and could influence both the design of future clinical trials and the goals of oncologists treating cancer.
Pancreatic cancer is a particularly deadly form of disease, and patients have few options for effective treatment. But a new Yale Cancer Center study has identified a gene that is critical to pancreatic cancer cell growth, revealing a fresh target for new therapies.
With the arrival of two revolutionary treatment strategies, immunotherapy and personalized medicine, cancer researchers have found new hope — and a problem that is perhaps unprecedented in medical research.
Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center at Yale School of Medicine and Yale Cancer Center.
Fred Hutchinson Cancer Research Center is launching a new integrated research center to prevent and find cures for cancers caused by infectious agents. It will be led by Dr. Denise Galloway, a Fred Hutch microbiologist whose research paved the way for the HPV vaccine, which prevents cervical, throat and other cancers.
Cancer immunotherapies that block two different checkpoints on T cells launch immune attacks on cancer by expanding distinct types of T cell that infiltrate tumors, researchers from The University of Texas MD Anderson Cancer Center report in the journal Cell.
Together with the NCCN Guidelines for Patients®: Colon Cancer, these free resources aid in decision-making for patients with colon and rectal cancers.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right